Comparison of Insulin With or Without Continuation of Oral Hypoglycemic Agents in the Treatment of Secondary Failure in NIDDM Patients
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Optimal insulin regimens for non-insulin-dependent diabetes mellitus (NIDDM) patients with secondary failure are controversial. We evaluated the efficacy, side effects, and quality of life of patients receiving insulin either alone or in combination with their previous oral Hypoglycemic agents (OHAs). RESEARCH DESIGN AND METHODS: Fifty-three Chinese patients with NIDDM (mean age 53.9 ± 12.6 years, duration of diabetes 9.0 ± 4.9 years, body wt 60.4 ± 13.3 kg with corresponding body mass index 24.2 ± 4.3 kg/m2, receiving the maximum dose of sulfonylurea and/or metformin) were confirmed to have OHA failure. Twenty-seven patients were randomized to continue OHAs and were given additional bedtime insulin (combination group); 26 patients were randomized to insulin therapy alone with twice–daily insulin (insulin group). Insulin doses were increased incrementally, aiming at fasting plasma glucose (FPG) <7.8 mmol/l during a stabilization period of up to 8 weeks. Insulin dosage, body weight, glycemie control, and quality of life were assessed before and at 3 and 6 months after stabilization. RESULTS: Both groups showed similar improvement of glycemie control. For the combination group, FPG decreased from 13.5 ± 2.7 to 8.9 ± 3.0 mmol/l at 3 months (P < 0.0001) and to 8.6 ± 2.5 mmol/l at 6 months (P < 0.0001). For the insulin group, FPG decreased from 13.5 ± 3.6 to 7.5 ± 3.0 mmol/l at 3 months (P < 0.0001) and to 9.8 ± 3.5 mmol/l at 6 months (P < 0.0001). No significant differences were observed between the groups. Similarly, both groups had significant improvement of fructosamine and glycosylated hemoglobin (HbAlc). Fructosamine fell from a mean of 458 to 365 μmol/l at 3 months (P < 0.0001) and to 371 μmol/l at 6 months (P < 0.0001) and from 484 to 325 μmol/1 at 3 months (P < 0.0001) and to 350 μmol/l at 6 months (P < 0.0001) for the combination and insulin groups, respectively. HbA1cdecreased from 10.2 to 8.4% at 3 months (P < 0.0001) and to 8.7% at 6 months (P < 0.0001) in the combination group and from 10.7 to 7.8% at 3 months (P < 0.0001) and to 8.4% at 6 months (P < 0.0001) in the insulin group. Despite similar improvement of glycemia, insulin requirements were very different. At 3 months, the combination group was receiving a mean of 14.4 U/day compared with 57.5 U/day in the insulin group (P < 0.0001). Similar findings were observed at 6 months (15.0 vs. 57.2 U/day, P < 0.0001). Both groups gained weight. However, for the combination group, weight gain was 1.6 ± 1.8 kg at 3 months and 2.1 ± 2.5 kg at 6 months (both P < 0.0001 vs. baseline), whereas for the insulin group, weight gain was 3.5 ± 4.3 and 5.2 ±4.1 kg, respectively (both P < 0.0001 vs. baseline). Weight gain was significantly greater in the insulin group (P < 0.05 at 3 months, and P < 0.005 at 6 months). Fasting plasma triglyceride decreased in the insulin group (1.8 ± 1.0 to 1.4 ± 0.8 mmol/l at 3 months [P < 0.005] and to 1.4 ± 0.7 mmol/l at 6 months [P < 0.02]) but not in the combination group. No changes were observed in total and high-density lipoprotein cholesterol. No severe Hypoglycemic reactions were recorded in either group. Mild reactions occurred with similar frequency in both groups. Well-being and quality of life improved significantly in both groups. The majority of patients (82.7%) wanted to continue insulin beyond 6 months, irrespective of the treatment group. CONCLUSIONS: in NIDDM patients with secondary OHA failure, therapy with a combination of OHAs and insulin and with insulin alone was equally effective and well tolerated. However, combination therapy was associated with a lower insulin dose and less weight gain. Combination treatment may be considered when OHA failure occurs as a potential intermediate stage before full insulin replacement.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Early Metabolic Defects in Persons at Increased Risk for Non-Insulin-Dependent Diabetes Mellitus
Eriksson, J., Franssila-Kallunki, A., Ekstrand, A., Saloranta, C., Widén, E., Schalin, C., & Groop, L. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908103210601 · Cited by 807 · cited 1×
“CONCLUSIONS— It is now generally accepted that NIDDM patients are characterized by both insulin resistance and insulin deficiency although the relative contribution from each may vary between patients (10-14).”
BackgroundImpaired Glucose Tolerance as a Disorder of Insulin Action
Lillioja, S., Mott, D. M., Howard, B. V., Bennett, P. H., Yki-Järvinen, H., Freymond, D., Nyomba, B. L., Zurlo, F., Swinburn, B., & Bogardus, C. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805123181901 · Cited by 578 · cited 1×
“CONCLUSIONS— It is now generally accepted that NIDDM patients are characterized by both insulin resistance and insulin deficiency although the relative contribution from each may vary between patients (10-14).”
BackgroundComparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus
Yki-Järvinen, H., Kauppila, M., Kujansuu, E., Lahti, J., Marjanen, T., Niskanen, L., Rajala, S., Ryysy, L., Salo, S., Seppälä, P., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199211123272005 · Cited by 324 · cited 3×
“Similar findings, but to a lesser extent, are demonstrated by several recent studies using a parallel or crossover design and similar methodology that have compared combination therapy with insulin therapy (5,23-25).”
BackgroundResult
Cited by
Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347
Pharmacologic Therapy for Type 2 Diabetes Mellitus
DeFronzo, R. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-4-199908170-00008 · Cited by 1,173
“In patients with type 2 diabetes that was inadequately controlled with metformin alone, addition of bedtime NPH insulin compared with switching to a multiple-insulin injection regimen produced equivalent glycemic control (167).”
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter (posthumous), E. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002967.pub4 · Cited by 893
Metadata
- Authors
- Chow, C.-C., Tsang, L. W. W., Sorensen, J. P., & Cockram, C. S.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 1995-03-01
- Volume
- 18
- Issue
- 3
- Pages
- 307-314
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W1974657065
- Cited by
- 109
- References
- 3
- FWCI
- 3.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.